4 Analysts Have This to Say About Integra Lifesciences
Portfolio Pulse from Benzinga Insights
Integra Lifesciences (NASDAQ:IART) has been rated by 4 analysts in the last quarter, with 1 bullish, 1 indifferent, and 2 somewhat bearish ratings. The average 12-month price target among these analysts is $42.5, with a high of $50.00 and a low of $37.00. This target remains unchanged from the previous average. Analyst ratings are based on predictions of a company's future earnings and revenue, and are updated quarterly or after major company events.
November 14, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Integra Lifesciences has a mixed outlook from analysts with 1 bullish, 1 indifferent, and 2 somewhat bearish ratings. The average price target is $42.5, unchanged from the previous target.
The unchanged price target and mixed analyst ratings suggest a neutral short-term impact on IART's stock price. The balance between bullish and bearish sentiments indicates that there is no strong consensus driving the stock in either direction.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100